SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hirschberg Angelica L)
 

Sökning: WFRF:(Hirschberg Angelica L) > Use of metformin to...

  • Løvvik, Tone S.Norwegian Univ Sci & Technol, Dept Clin & Mol Med, N-7491 Trondheim, Norway;St Olavs Univ Hosp, Dept Gynaecol & Obstet, Trondheim, Norway (författare)

Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2) : a randomised, double-blind, placebo-controlled trial

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • Elsevier,2019
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-157946
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-157946URI
  • https://doi.org/10.1016/S2213-8587(19)30002-6DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-381111URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:140551724URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: Women with polycystic ovary syndrome (PCOS) have an increased risk of pregnancy complications. Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group. The aim of this third randomised trial (PregMet2) was to test the hypothesis that metformin prevents late miscarriage and preterm birth in women with PCOS.Methods: PregMet2 was a randomised, placebo-controlled, double-blind, multicentre trial done at 14 hospitals in Norway, Sweden, and Iceland. Singleton pregnant women with PCOS aged 18-45 years were eligible for inclusion. After receiving information about the study at their first antenatal visit or from the internet, women signed up individually to participate in the study. Participants were randomly assigned (1: 1) to receive metformin or placebo by computer-generated random numbers. Randomisation was in blocks of ten for each country and centre; the first block had a random size between one and ten to assure masking. Participants were assigned to receive oral metformin 500 mg twice daily or placebo during the first week of treatment, which increased to 1000 mg twice daily or placebo from week 2 until delivery. Placebo tablets and metformin tablets were identical and participants and study personnel were masked to treatment allocation. The primary outcome was the composite incidence of late miscarriage (between week 13 and week 22 and 6 days) and preterm birth (between week 23 and week 36 and 6 days), analysed in the intention-to-treat population. Secondary endpoints included the incidence of gestational diabetes, preeclampsia, pregnancy-induced hypertension, and admission of the neonate to the neonatal intensive care unit. We also did a post-hoc individual participant data analysis of pregnancy outcomes, pooling data from the two previous trials with the present study. The study was registered with ClinicalTrials. gov, number NCT01587378, and EudraCT, number 2011-002203-15.Findings: The study took place between Oct 19, 2012, and Sept 1, 2017. We randomly assigned 487 women to metformin (n=244) or placebo (n=243). In the intention-to-treat analysis, our composite primary outcome of late miscarriage and preterm birth occurred in 12 (5%) of 238 women in the metformin group and 23 (10%) of 240 women in the placebo group (odds ratio [OR] 0.50, 95% CI 0.22- 1.08; p = 0.08). We found no significant differences for our secondary endpoints, including incidence of gestational diabetes (60 [25%] of 238 women in the metformin group vs 57 [24%] of 240 women in the placebo group; OR 1.09, 95% CI 0.69-1.66; p=0.75). We noted no substantial between-group differences in serious adverse events in either mothers or offspring, and no serious adverse events were considered drug-related by principal investigators. In the post-hoc pooled analysis of individual participant data from the present trial and two previous trials, 18 (5%) of 397 women had late miscarriage or preterm delivery in the metformin group ]compared with 40 (10%) of 399 women in the placebo group (OR 0.43, 95% CI 0.23-0.79; p=0.004).Interpretation: In pregnant women with PCOS, metformin treatment from the late first trimester until delivery might reduce the risk of late miscarriage and preterm birth, but does not prevent gestational diabetes.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Carlsen, Sven M.Norwegian Univ Sci & Technol, Dept Clin & Mol Med, N-7491 Trondheim, Norway;St Olavs Univ Hosp, Dept Endocrinol, Trondheim, Norway (författare)
  • Salvesen, ØyvindNorwegian Univ Sci & Technol, Dept Publ Hlth & Nursing, Trondheim, Norway (författare)
  • Steffensen, BerglindUniv Hosp Iceland, Dept Obstet & Gynaecol, Reykjavik, Iceland (författare)
  • Bixo, MarieUmeå universitet,Obstetrik och gynekologi,Umea Univ, Dept Clin Sci, Umea, Sweden(Swepub:umu)mabi0001 (författare)
  • Gomez-Real, FranciscoHaukeland Hosp, Dept Obstet & Gynaecol, Bergen, Norway;Univ Bergen, Dept Clin Sci, Bergen, Norway (författare)
  • Lennebotn, MarianneHaukeland Hosp, Dept Obstet & Gynaecol, Bergen, Norway (författare)
  • Hestvold, Kristin, VVestre Viken Hosp Trust, Womens Clin, Drammen, Norway (författare)
  • Zabielska, RenataVestfold Hosp Trust, Womens Clin, Tonsberg, Norway (författare)
  • Hirschberg, Angelica L.Karolinska Institutet (författare)
  • Trouva, AnastasiaKarolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden (författare)
  • Thorarinsdottir, SolveigTelemark Hosp Trust, Womens Clink, Skien, Norway (författare)
  • Hjelle, SisselAlesund Hosp, Womens Clin, Alesund, Norway (författare)
  • Berg, Ann HildeInnlandet Hosp Trust, Womens Clink, Lillehammer, Norway (författare)
  • Andrae, FridaNordlands Hosp Trust, Womens Clin, Bodo, Norway (författare)
  • Sundström Poromaa, Inger,1964-Uppsala universitet,Reproduktiv hälsa(Swepub:uu)inspo702 (författare)
  • Molin, JohannaUmeå universitet,Obstetrik och gynekologi,Umea Univ, Dept Clin Sci, Umea, Sweden;Sadersjukhuset, Stockholm, Sweden(Swepub:umu)jomo0065 (författare)
  • Underdal, MariaNorwegian Univ Sci & Technol, Dept Clin & Mol Med, N-7491 Trondheim, Norway;St Olavs Univ Hosp, Dept Gynaecol & Obstet, Trondheim, Norway (författare)
  • Vanky, EszterNorwegian Univ Sci & Technol, Dept Clin & Mol Med, N-7491 Trondheim, Norway;St Olavs Univ Hosp, Dept Gynaecol & Obstet, Trondheim, Norway (författare)
  • Salvesen, O (författare)
  • Norwegian Univ Sci & Technol, Dept Clin & Mol Med, N-7491 Trondheim, Norway;St Olavs Univ Hosp, Dept Gynaecol & Obstet, Trondheim, NorwayNorwegian Univ Sci & Technol, Dept Clin & Mol Med, N-7491 Trondheim, Norway;St Olavs Univ Hosp, Dept Endocrinol, Trondheim, Norway (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:The Lancet Diabetes and Endocrinology: Elsevier7:4, s. 256-2662213-85872213-8595

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy